rs533899702
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM1PM2PM5PP3_Moderate
The NM_001048174.2(MUTYH):c.470G>A(p.Arg157Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00000496 in 1,614,156 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R157W) has been classified as Likely pathogenic.
Frequency
Consequence
NM_001048174.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MUTYH | NM_001048174.2 | c.470G>A | p.Arg157Gln | missense_variant | 7/16 | ENST00000456914.7 | NP_001041639.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MUTYH | ENST00000456914.7 | c.470G>A | p.Arg157Gln | missense_variant | 7/16 | 1 | NM_001048174.2 | ENSP00000407590.2 | ||
ENSG00000288208 | ENST00000671898.1 | n.1058G>A | non_coding_transcript_exon_variant | 11/21 | ENSP00000499896.1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152154Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.00000795 AC: 2AN: 251444Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135916
GnomAD4 exome AF: 0.00000410 AC: 6AN: 1461884Hom.: 0 Cov.: 36 AF XY: 0.00000413 AC XY: 3AN XY: 727246
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152272Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74454
ClinVar
Submissions by phenotype
Familial adenomatous polyposis 2 Pathogenic:1Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | May 30, 2024 | This missense variant replaces arginine with glutamine at codon 185 of the MUTYH protein. This variant is also known as c.512G>A (p.Arg171Gln) based on an alternative transcript (NM_001048171). Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). A complementation assay using E. Coli has shown that the variant protein leads to increased spontaneous mutations compared to wild type protein (PMID: 25820570). This variant has been reported in the compound heterozygous state in an individual affected with attenuated familial adenomatous polyposis (PMID: 16287072). This variant has also been reported in individuals affected with biliary tract cancer (PMID: 31666926) and colorectal cancer (PMID: 33309985). This variant has been identified in 2/251444 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 14, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 185 of the MUTYH protein (p.Arg185Gln). This variant is present in population databases (rs533899702, gnomAD 0.006%). This missense change has been observed in individual(s) with familial adenomatous polyposis or gallbladder cancer (PMID: 16287072, 31666926). ClinVar contains an entry for this variant (Variation ID: 481821). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects MUTYH function (PMID: 25820570). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 01, 2021 | Variant summary: MUTYH c.554G>A (p.Arg185Gln) results in a conservative amino acid change located in the HhH (helix hairpin helix)-GPD domain (IPR003265) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251444 control chromosomes. In our ascertainment, c.554G>A has been reported in the literature as 1. a biallelic compound heterozygous genotype in a APC mutation negative patient with 50 polyps and no personal history of colorectal cancer, but a family history of colorectal cancer (Russel_2006), 2. as an uninformative genotype (i.e., single variant) in a 59 year old male with gall bladder tumor and a family history of one biliary tract cancer in first or second degree relatives (Terashima_2019), 3. with an uninformative genotype but a classification of Pathogenic in a single case within a cohort of unselected Japanese CRC patients and in a population control within the same study (Fujita_2020). These data do not allow firm conclusions about variant significance. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in a functionally defective base excision repair (BER) activity by a MutY-deficient Ecoli complementation assay (Komine_2015). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance citing overlapping but not identical evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Mar 30, 2023 | This missense variant replaces arginine with glutamine at codon 185 of the MUTYH protein. This variant is also known as c.512G>A (p.Arg171Gln) based on an alternative transcript (NM_001048171). Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). A complementation assay using E. Coli has shown that the variant protein leads to increased spontaneous mutations compared to wild type protein (PMID: 25820570). This variant has been reported in the compound heterozygous state in an individual affected with attenuated familial adenomatous polyposis (PMID: 16287072). This variant has also been reported in individuals affected with biliary tract cancer (PMID: 31666926) and colorectal cancer (PMID: 33309985). This variant has been identified in 2/251444 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 02, 2023 | The p.R185Q variant (also known as c.554G>A), located in coding exon 7 of the MUTYH gene, results from a G to A substitution at nucleotide position 554. The arginine at codon 185 is replaced by glutamine, an amino acid with highly similar properties. This alteration has been reported in a compound heterozygous state in a 60-year-old Swiss female attenuated familial adenomatous polyposis (AFAP) patient and was not observed in 200 chromosomes from Swiss control samples (Russell AM et al. Int. J. Cancer. 2006 Apr;118:1937-40). This alteration was also observed in a Japanese population cohort of 2049 individuals who underwent whole-genome sequencing (Yamaguchi-Kabata Y et al. J Hum Genet, 2018 Feb;63:213-230) and in a cohort of patients diagnosed with biliary tract carcinoma undergoing multigene panel testing for hereditary cancer risk (Terashima T et al. Oncotarget, 2019 Oct;10:5949-5957). Furthermore, this variant was present in 0/1005 Japanese pancreatic cancer patients and in 1/23705 controls (Mizukami K et al. EBioMedicine, 2020 Oct;60:103033) and was identified in 1/12501 unselected Japanese colorectal cancer patients and in 1/23695 controls (Fujita M et al. Clin Gastroenterol Hepatol, 2022 Sep;20:2132-2141.e9). Of note, this variant is also referred to as c.545G>A (p.Arg182Gln) and p.R171Q in the literature. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Aug 01, 2023 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies suggest a damaging effect: reduced protein levels compared to wildtype (Komine et al., 2015); Observed in individuals with colorectal cancer, biliary tract carcinoma, or pancreatic cancer (Poulsen et al., 2008; Terashima et al., 2019; Mizukami et al., 2020); Observed in an individual with attenuated polyposis and a second pathogenic variant in MUTYH (Russell et al., 2006); Also known as c.545G>A, p.(R171Q); This variant is associated with the following publications: (PMID: 29192238, 31666926, 33309985, 32980694, 25820570, 19506731, 16287072) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at